Liquidia (NASDAQ:LQDA) Earns “Buy” Rating from Needham & Company LLC

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports. They presently have a $19.00 target price on the stock. Needham & Company LLC’s target price points to a potential upside of 52.49% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Wells Fargo & Company initiated coverage on shares of Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. Lifesci Capital started coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective for the company. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Liquidia currently has an average rating of “Buy” and a consensus price target of $25.38.

Liquidia Stock Up 0.5 %

Liquidia stock opened at $12.46 on Thursday. The company has a market capitalization of $1.05 billion, a PE ratio of -7.64 and a beta of 0.23. The firm’s fifty day moving average is $11.07 and its 200 day moving average is $11.02. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.99.

Insider Buying and Selling at Liquidia

In other news, CFO Michael Kaseta sold 3,892 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the completion of the transaction, the chief financial officer now directly owns 311,076 shares of the company’s stock, valued at $3,456,054.36. This represents a 1.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $89,468.83. Following the sale, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,007 shares of company stock worth $245,780. Corporate insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its position in Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after buying an additional 123,402 shares during the period. Whitefort Capital Management LP increased its stake in shares of Liquidia by 119.8% during the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after purchasing an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after purchasing an additional 230,820 shares during the period. Barclays PLC raised its holdings in shares of Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after purchasing an additional 72,591 shares during the period. Finally, Sapient Capital LLC purchased a new position in Liquidia in the third quarter valued at approximately $1,336,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).